Ghrelin (pr. GREL-in), the "hunger hormone", is a peptide produced by ghrelin cells in the gastrointestinal tract which functions as a neuropeptide in the central nervous system. Beyond regulating hunger, ghrelin also plays a significant role in regulating the distribution and rate of use of energy.
When the stomach is empty ghrelin is secreted, and when it is stretched secretion stops. It acts on hypothalamic brain cells both to increase hunger, and to increase gastric acid secretion and gastrointestinal motility to prepare the body for food intake.
The receptor for ghrelin is found on the same cells in the brain as the receptor for leptin, the satiety hormone that has opposite effects from ghrelin.
Ghrelin is encoded by the GHRL gene and is produced from the presumed cleavage of the prepropeptide ghrelin/obestatin. Full-length preproghrelin is homologous to promotilin and both are members of the motilin family.
Ghrelin was discovered after the ghrelin receptor (called growth hormone secretagogue type 1A receptor or GHSR) was discovered in 1996 and was reported in 1999. The hormone name is based on its role as a growth hormone-releasing peptide, with reference to the Proto-Indo-European root ghre, meaning to grow. (Growth Hormone Release-Inducing = Ghrelin)
Gene, transcription products, and structure
Preproghrelin (green and blue) and ghrelin (green).
The GHRL gene produces mRNA which has four exons. Five products arise: the first is the 117-amino acid preproghrelin. (It is homologous to promotilin; both are members of the motilin family). It is cleaved to produce proghrelin which is cleaved to produce a 28-amino acid ghrelin (unacylated) and C-ghrelin(acylated). Obestatin is presumed to be cleaved from C-ghrelin.
Ghrelin only becomes active when caprylic (octanoic) acid is linked posttranslationally to serine at the 3-position by the enzyme ghrelin O-acyltransferase (GOAT). It is located on the cell membrane of ghrelin cells in the stomach and pancreas. The non-octanoylated form is desacyl ghrelin. It does not activate the GHSR receptor but does have other effects: cardiac, anti-ghrelin, appetite stimulation, and inhibition of hepatic glucose output Side-chains other than octanoyl have also been observed: these can also trigger the ghrelin receptor. In particular, decanoyl ghrelin has been found to constitute a significant portion of circulating ghrelin in mice, but as of 2011 its presence in humans has not been established.
The ghrelin cell is also known as an A-like cell (pancreas), X-cell (for unknown function), X/A-like cell (rats), Epsilon cell (pancreas), P/D sub 1 cell (humans) and Gr cell (abbreviation for ghrelin cell).
Ghrelin cells are found mainly in the stomach  and duodenum, but also in the jejunum, lungs, pancreatic islets, gonads, adrenal cortex, placenta, and kidney.
Ghrelin cells are found in oxyntic glands (20% of cells), pyloric glands, and small intestine. They are ovoid cells with granules. They have gastrin receptors. They produce nesfatin-1, another food intake limiting hormone in addition to ghrelin. Ghrelin cells are not terminally differentiated in the pancreas: they are progenitor cells that can give rise to A-cells, PP cells and Beta-cells there.
Function and mechanism of action
Ghrelin is a participant in the complex process of energy homeostasis which adjusts both energy input - by adjusting hunger signals - and energy output - by adjusting the proportion of energy going to ATP production, fat storage, and short-term heat loss (all energy input is ultimately dissipated as heat). The net result of these processes is reflected in body weight, and is under continuous monitoring and adjustment based on metabolic signals and needs and at any given moment in time may be in equilibrium or disequilibrium.. Gastric-brain communication is an essential part of energy homeostasis, and several communication pathways are probable, including the gastric intracellular mTOR/S6K1 pathway mediating the interaction among ghrelin, nesfatin and endocannabinoid gastric systems, and both afferent and efferent vagal signals.
Ghrelin and synthetic ghrelin mimetics (the growth hormone secretagogues) increase appetite and fat mass by triggering receptors in the arcuate nucleus that include the orexigenic neuropeptide Y (NPY) neurons. Ghrelin-responsiveness of these neurons is both leptin- and insulin-sensitive. Ghrelin reduces the mechanosensitivity of gastric vagalafferents, so they are less sensitive to gastric distension.
In addition to its function in energy homeostasis, ghrelin also activates the mesolimbic cholinergic-dopaminergic reward link, a circuit that communicates the hedonic and reinforcing aspects of natural rewards, such as food and addictive drugs such as ethanol. Hypothalamic ghrelin signalling is required for reward from alcohol and palatable/rewarding foods.
Ghrelin also improves endothelial function and inhibits proatherogenic changes in cell cultures. It activates the endothelial isoform of nitric oxide synthase in a pathway that depends on various kinases including Akt.
Ghrelin has been linked to inducing appetite and feeding behaviors. Circulating ghrelin levels are the highest right before a meal and the lowest right after. Injections of ghrelin in both humans and rats have been shown to increase food intake in a dose-dependent manner. So the more ghrelin that is injected the more food that is consumed. However, ghrelin does not increase meal size, only meal number. Ghrelin injections also increase an animal's motivation to seek out food, behaviors including increased sniffing, foraging for food, and hoarding food. Body weight is regulated through energy balance, the amount of energy taken in versus the amount of energy expended over an extended period of time. Studies have shown that ghrelin levels are negatively correlated with weight. This data suggests that ghrelin functions as an adiposity signal, a messenger between the body's energy stores and the brain. When a person loses weight their ghrelin levels increase, which causes increased food consumption and weight gain. On the other hand, when a person gains weight, ghrelin levels drop, leading to a decrease in food consumption and weight loss. This suggests that ghrelin acts as a body weight regulator, continuously keeping one's body weight and energy stores in check.
Blood levels are in the pmol/l range. Both active and total ghrelin can be measured. Circulating ghrelin concentrations rise before eating and fall afterward, more strongly in response to protein and carbohydrate than to lipids.
The ghrelin receptor
The ghrelin receptor GHSR1a (a splice-variant of the growth hormone secretagogue receptor) is involved in mediating a wide variety of biological effects of ghrelin, including: stimulation of growth hormone release, increase in hunger, modulation of glucose and lipid metabolism, regulation of gastrointestinal motility and secretion, protection of neuronal and cardiovascular cells, and regulation of immune function. They are present in high density in the hypothalamus and pituitary, on the vagus nerve (on both afferent cell bodies and afferent nerve endings) and throughout the gastrointestinal tract.
Sites of action
Ghrelin promotes intestinal cell proliferation and inhibits apoptosis during inflammatory states and oxidative stress. It also suppresses pro-inflammatory mechanisms and augments anti-inflammatory mechanisms, thus creating a possibility of its therapeutic use in various gastrointestinal inflammatory conditions, including colitis, ischemia reperfusion injury, and sepsis. Animal models of colitis, ischemia reperfusion, and sepsis-related gut dysfunction have been shown to benefit from therapeutic doses of ghrelin. It has also been shown to have regenerative capacity and is beneficial in mucosal injury to the stomach.
Ghrelin promotes gastrointestinal and pancreatic malignancy.
Ghrelin acts on its receptor in the pancreas to inhibit glucose-stimulated insulin secretion.
The entire ghrelin system (dAG, AG, GHSR and GOAT) has a gluco-regulatory action.
Learning and memory
The hippocampus plays a significant role in neurotrophy: the cognitive adaptation to changing environments and the process of learning and it is a potent stimulator of growth hormone.Animal models indicate that ghrelin may enter the hippocampus from the bloodstream, altering nerve-cellconnections, and so altering learning and memory. It is suggested that learning may be best during the day and when the stomach is empty, since ghrelin levels are higher at these times. A similar effect on human memory performance is possible. In rodents, X/A-like cells produce ghrelin.
Ghrelin has been shown to have implications for depression prevention. Antidepressant-like attributes were demonstrated when mice with high levels of ghrelin and mice with the ghrelin gene knocked out underwent social defeat stress and then were placed in the forced swim tank. Mice with elevated ghrelin swam more than ghrelin deficient mice. These ghrelin-deficient mice exhibited more social avoidance as well. These mice did not exhibit depression-like behaviors when injected with a commonly prescribed antidepressant, suggesting that ghrelin acts as a short-term natural adaptation against depression.
Short sleep duration is associated with high levels of ghrelin and obesity. An inverse relationship between the hours of sleep and blood plasma concentrations of ghrelin exists; as the hours of sleep increase, ghrelin levels trend lower and obesity is less likely.
Prior stress exposure heightens fear learning during Pavlovian fear conditioning. Stress-related increases in ghrelin circulation were shown to be necessary and sufficient for stress to increase fear learning. Ghrelin was found to be upregulated by stress even in the absence of adrenal hormones. Blocking the ghrelin receptor during stress abolished stress-related enhancement of fear memory without blunting other markers of stress. These results suggest that ghrelin is a novel branch of the stress response. Human studies are needed to translate the use of anti-ghrelin treatments to prevent stress-induced psychiatric disorders.
Ghrelin is produced early by the fetal lung and promotes lung growth.
Cord blood levels of active and total ghrelin show a correlation between ghrelin levels and birth weight.
Ghrelin gene products have several actions on acute and chronic inflammation and autoimmunity, with promising therapeutic applications.
Anorexia and obesity
Ghrelin levels in the plasma of obese individuals are lower than those in leaner individuals, suggesting that ghrelin does not contribute to obesity, except in the cases of Prader-Willi syndrome-induced obesity, where high ghrelin levels are correlated with increased food intake.
Those with anorexia nervosa have high plasma levels of ghrelin compared to both the constitutionally thin and normal-weight controls.
Intravenous administration of ghrelin to anorexia nervosa patients increased food intake by 12–36% over the trial period.
The level of ghrelin increases during the time of day from midnight to dawn in thinner people, which suggests there is a flaw in the circadian rhythm of obese individuals.
Ghrelin levels reflect release in a circadian rhythm which can be interrupted by exposure to light at night.
Short sleep duration may also lead to obesity, through an increase of appetite via hormonal changes.
Lack of sleep increases ghrelin, and decreases leptin, both effects producing increased hunger and obesity.
Ghrelin levels are high in patients with cancer-induced cachexia.
Gastric bypass surgery
Gastric bypass surgery not only reduces the gut's capacity for food but also dramatically lowers ghrelin levels compared to both lean controls and those that lost weight through dieting alone. However, studies are conflicting as to whether or not ghrelin levels return to close to normal with gastric bypass patients in the long term after weight loss has stabilized. Bariatric surgeries involving vertical sleeve gastrectomy reduce plasma ghrelin levels by about 60% in the long term.
Medical management of obesity
Ghrelin is not FDA approved for any indication. In rodents and pigs, an anti-obesity vaccine has been developed. It blocks the ghrelin receptor.
Future clinical uses
Synthetic ghrelin administration for cachexia of any cause  and for hemodialysis patients is being investigated.
^Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, Fujimiya M (2004). "Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ". FASEB J.18 (3): 439–56. doi:10.1096/fj.03-0641rev. PMID15003990.
^ abDickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E (2011). "The role of the central ghrelin system in reward from food and chemical drugs". Mol. Cell. Endocrinol.340 (1): 80–87. doi:10.1016/j.mce.2011.02.017. PMID21354264.
^Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, Fujimiya M (March 2004). "Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ". FASEB J.18 (3): 439–56. doi:10.1096/fj.03-0641rev. PMID15003990.
^ abcSeim I, Amorim L, Walpole C, Carter S, Chopin LK, Herington AC (2010). "Ghrelin gene-related peptides: multifunctional endocrine / autocrine modulators in health and disease". Clin Exp Pharmacol Physiol.37 (1): 125–31. doi:10.1111/j.1440-1681.2009.05241.x. PMID19566830.
^Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F, Ghé C, Deghenghi R, Ghigo E, Muccioli G (2003). "Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin". Eur J Pharmacol.476 (1–2): 87–95. doi:10.1016/S0014-2999(03)02083-1. PMID12969753.
^Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, Abribat T, Van Der Lely AJ, Ghigo E (2004). "Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans". J Clin Endocrinol Metab.89 (6): 3062–5. doi:10.1210/jc.2003-031964. PMID15181099.
^Toshinai K, Yamaguchi H, Sun Y, Smith RG, Yamanaka A, Sakurai T, Date Y, Mondal MS, Shimbara T, Kawagoe T, Murakami N, Miyazato M, Kangawa K, Nakazato M (2006). "Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor". Endocrinology.147 (5): 2306–14. doi:10.1210/en.2005-1357. PMID16484324.
^Gauna C, Delhanty PJ, Hofland LJ, Janssen JA, Broglio F, Ross RJ, Ghigo E, van der Lely AJ (2005). "Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes". J Clin Endocrinol Metab.90 (2): 1055–6. doi:10.1210/jc.2004-1069. PMID15536157.
^Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K (October 2001). "Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans". J. Clin. Endocrinol. Metab.86 (10): 4753–8. doi:10.1210/jcem.86.10.7885. PMID11600536.
^Suckale J, Solimena M (2008). "Pancreas islets in metabolic signaling--focus on the beta-cell". Front. Biosci.13: 7156–71. doi:10.2741/3218. PMID18508724.
^Simonsson M, Eriksson S, Håkanson R, Lind T, Lönroth H, Lundell L, O'Connor DT, Sundler F (1988). "Endocrine cells in the human oxyntic mucosa. A histochemical study". Scand. J. Gastroenterol.23 (9): 1089–99. doi:10.3109/00365528809090174. PMID2470131.
^Hewson AK, Dickson SL (2000). "Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats". J Neuroendocrinol.12 (11): 1047–1049. doi:10.1046/j.1365-2826.2000.00584.x. PMID11069119.
^Dickson SL, Luckman SM (1997). "Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6". Endocrinology.138 (2): 771–777. doi:10.1210/en.138.2.771. PMID9003014.
^ abHewson AK, Tung LY, Connell DW, Tookman L, Dickson SL (2002). "The rat arcuate nucleus integrates peripheral signals provided by leptin, insulin, and a ghrelin mimetic". Diabetes.51 (12): 3412–3419. doi:10.2337/diabetes.51.12.3412. PMID12453894.
^ abPage A, Slattery J, Milte C, Laker R, O'Donnell T, Dorian C, Brierley S, Blackshaw LA (2007). "Ghrelin selectively reduces mechanosensitivity of upper gastrointestinal vagal afferents". Am J Physiol Gastrointest Liver Physiol.292 (5): 1376–1384. doi:10.1152/ajpgi.00536.2006. PMID17290011.
^Jerlhag E, Egecioglu, E, Dickson SL, Andersson M, Svensson L, Engel JA (2004). "Ghrelin Stimulates Locomotor Activity and Accumbal Dopamine-Overflow via Central Cholinergic Systems in Mice: Implications for its Involvement in Brain Reward". Addiction Biology11 (1): 45–54. doi:10.1111/j.1369-1600.2006.00002.x. PMID16759336.
^ abYokota I, Kitamura S, Hosoda H, Kotani Y, Kangawa K (2005). "Concentration of the n-octanoylated active form of ghrelin in fetal and neonatal circulation". Endocr. J.52 (2): 271–6. doi:10.1507/endocrj.52.271. PMID15863960.
^Waseem T, Duxbury M, Ito H, Rocha F, Lautz D, Whang E, Ashley SW, Robinson MK (September 2004). "Ghrelin ameliorates TNF-a induced anti-proliferative and pro-apoptotic effects and promotes intestinal epithelial restitution". Journal of the American College of Surgeons199 (3 Supplement): 16. doi:10.1016/j.jamcollsurg.2004.05.018.
^Işeri SO, Sener G, Yüksel M, Contuk G, Cetinel S, Gedik N, Yegen BC (December 2005). "Ghrelin against alendronate-induced gastric damage in rats". J. Endocrinol.187 (3): 399–406. doi:10.1677/joe.1.06432. PMID16423819.
^ abHeppner KM, Tong J (2014). "Regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions". Eur. J. Endocrinol.171 (1): R21–32. doi:10.1530/EJE-14-0183. PMID24714083.
^ abDiano S, Farr SA, Benoit SC, McNay EC, da Silva I, Horvath B, Gaskin FS, Nonaka N, Jaeger LB, Banks WA, Morley JE, Pinto S, Sherwin RS, Xu L, Yamada KA, Sleeman MW, Tschöp MH, Horvath TL (March 2006). "Ghrelin controls hippocampal spine synapse density and memory performance". Nat. Neurosci.9 (3): 381–8. doi:10.1038/nn1656. PMID16491079. Lay summary – Science Blog.
^Atcha Z, Chen WS, Ong AB, Wong FK, Neo A, Browne ER, Witherington J, Pemberton DJ (2009). "Cognitive enhancing effects of ghrelin receptor agonists". Psychopharmacology (Berl).206 (3): 415–27. doi:10.1007/s00213-009-1620-6. PMID19652956.
^Meyer RM, Burgos-Robles A, Liu E, Correia SS, Goosens KA (October 2013). "A ghrelin-growth hormone axis drives stress-induced vulnerability to enhanced fear". Mol. Psychiatry. doi:10.1038/mp.2013.135. PMID24126924. Lay summary – Massachusetts Institute of Technology News.
^Comninos AN, Jayasena CN, Dhillo WS (2014). "The relationship between gut and adipose hormones, and reproduction". Hum. Reprod. Update20 (2): 153–74. doi:10.1093/humupd/dmt033. PMID24173881.
^Santos M, Bastos P, Gonzaga S, Roriz JM, Baptista MJ, Nogueira-Silva C, Melo-Rocha G, Henriques-Coelho T, Roncon-Albuquerque R Jr, Leite-Moreira AF, De Krijger RR, Tibboel D, Rottier R, Correia-Pinto J (2006). "Ghrelin expression in human and rat fetal lungs and the effect of ghrelin administration in nitrofen-induced congenital diaphragmatic hernia". Pediatr Res59 (4 Pt 1): 531–7. doi:10.1203/01.pdr.0000202748.66359.a9. PMID16549524.
^ abCummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ (May 2002). "Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery". N. Engl. J. Med.346 (21): 1623–30. doi:10.1056/NEJMoa012908. PMID12023994.
^Goldstone AP, Thomas EL, Brynes AE, Castroman G, Edwards R, Ghatei MA, Frost G, Holland AJ, Grossman AB, Korbonits M, Bloom SR, Bell JD (April 2004). "Elevated fasting plasma ghrelin in prader-willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance". J. Clin. Endocrinol. Metab.89 (4): 1718–26. doi:10.1210/jc.2003-031118. PMID15070936.
^DelParigi A, Tschöp M, Heiman ML, Salbe AD, Vozarova B, Sell SM, Bunt JC, Tataranni PA (December 2002). "High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome". J. Clin. Endocrinol. Metab.87 (12): 5461–4. doi:10.1210/jc.2002-020871. PMID12466337.
^Hotta M, Ohwada R, Akamizu T, Shibasaki T, Takano K, Kangawa K (2009). "Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study". Endocr. J.56 (9): 1119–28. doi:10.1507/endocrj.K09E-168. PMID19755753.
^Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, Smith RG, Cunningham GR, Marcelli M (May 2005). "Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia". J. Clin. Endocrinol. Metab.90 (5): 2920–6. doi:10.1210/jc.2004-1788. PMID15713718.
^Cummings DE, Shannon MH (July 2003). "Ghrelin and Gastric Bypass: Is There a Hormonal Contribution to Surgical Weight Loss?". J Clin Endocrinol Metab.88 (7): 2999–3002. doi:10.1210/jc.2003-030705. PMID12843132.
^Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, Gfrerer L, Ludvik B, Zacherl J, Prager G. (May 2010). "Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin.". Obes Surg.20 (5): 535–40. doi:10.1007/s11695-009-0066-6. PMID20094819.
^Vizcarra JA, Kirby JD, Kim SK, Galyean ML (August 2007). "Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs". Domest Anim Endocrinol.33 (2): 176–89. doi:10.1016/j.domaniend.2006.05.005. PMID16793235.
^Ruperto M, Sánchez-Muniz FJ, Barril G (2014). "A clinical approach to the nutritional care process in protein-energy wasting hemodialysis patients". Nutr Hosp29 (4): 735–50. doi:10.3305/nh.2014.29.4.7222. PMID24679014.
Meyer RM, Burgos-Robles A, Liu E, Correia SS, Goosens KA (October 2013). "A ghrelin-growth hormone axis drives stress-induced vulnerability to enhanced fear". Mol. Psychiatry. doi:10.1038/mp.2013.135. PMID24126924.